To Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly for Subjects With HER2 Negative Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 04 Dec 2017 Status changed from active, no longer recruiting to completed.
- 30 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Oct 2017.
- 24 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 May 2017.